[1] 郭智,陈惠仁,刘晓东,等.单倍型异基因造血干细胞移植治疗儿童重型再生障碍性贫血[J].中华实用儿科临床杂志,2014,29(15): 1145-1148.[2] 王晓宁,张梅,贺鹏程,等.非血缘异基因造血干细胞移植治疗白血病21例临床观察[J].西安交通大学学报:医学版,2015,36(2): 280-284.[3] 王萌,徐衍,孙慧,等.移植物中CCR6+及CCR7+T细胞数量与异基因造血干细胞移植受者急性移植物抗宿主病发生的关系[J].郑州大学学报:医学版,2016,51(4):494-497.[4] 程永贵,杨广民,肖中平.CIK 细胞对急性髓细胞白血病微小残留病作用的研究[J].吉林医学,2012,33(8):1571-1574.[5] 张之南,沈悌.血液病诊断及疗效标准[M].3版.北京:科学出版社, 2008:103-121,131-139,147-148,157-163,220-228.[6] Ruggeri L, Mancusi A, Burchielli E, et al. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood Cells Mol Dis. 2008;40(1):84-90.[7] Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301(22):2349-2361.[8] Fernandez HF, Sun Z, Litzow MR, et al. Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin. Blood. 2011;117(20): 5306-5313.[9] Kim ST, Jung CW, Lee J, et al. Postremission therapy for acute myeloid leukemia in the first remission. Leuk Lymphoma. 2007;48(5):937-943.[10] Jing Y, Li H, Zhao Y, et al. Efficacy of allogeneic and autologous hematopoietic SCT in patients with AML after first complete remission. Bone Marrow Transplant. 2013;48(3):383-389.[11] 王荷花,冯四洲,王玫,等.急性白血病患者第一次完全缓解期自体和异基因造血干细胞移植疗效的比较[J].中华血液学杂志,2004, 25(7):389-392.[12] Hamadani M, Awan FT, Copelan EA. Hematopoietic stem cell transplantation in adults with acute myeloid leukemia. Biol Blood Marrow Transplant. 2008;14(5):556-567.[13] Loh YS, Koh LP, Tai BC, et al. Long-term follow-up of Asian patients younger than 46 years with acute myeloid leukemia in first complete remission: comparison of allogeneic vs. autologous hematopoietic stem cell transplantation. Leuk Lymphoma. 2007;48(1):72-79.[14] Michallet AS, Chelghoum Y, Thiebaut A, et al. Autologous hematopoietic stem cell transplantation for adults with acute myeloid leukemia in complete remission: the Edouard Herriot Hospital experience. Hematology. 2006;11(3):157-164.[15] 刘辉,常乃柏,顾惜春,等.自体造血干细胞移植治疗急性白血病的临床观察[J].临床血液学杂志,2009,22(1):24-26.[16] 冯四洲,魏嘉璘,邹德惠,等.自体造血干细胞移植治疗急性白血病患者143例疗效分析[J].内科急危重症杂志,2005,11(3):112-115.[17] Linn YC, Wang SM, Hui KM. Comparative gene expression profiling of cytokine-induced killer cells in response to acute myloid leukemic and acute lymphoblastic leukemic stimulators using oligonucleotide arrays. Exp Hematol. 2005;33(6):671-681.[18] 薛重重,杨丽萍,徐新,等.血液肿瘤患者AHSCT后DC/CIK免疫治疗的疗效观察[J].中华全科医学,2012,10(3):341-342.[19] 王玲,史春雷,李颖,等.恶性血液病自体造血干细胞移植后DC-CIK细胞预防复发探讨[J].青岛大学医学院学报,2010,46(2):142-144.[20] 苏毅,易海,范方毅,等.荷载自体白血病抗原的DC-CIK细胞预防急性髓细胞性白血病自体造血干细胞移植后复发的临床研究[J].中国输血杂志,2010,23(12):1024-1028.[21] Introna M, Borleri G, Conti E, et al. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica. 2007;92(7):952-959.[22] Nishimura R, Baker J, Beilhack A, et al. In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood. 2008;112(6): 2563-2574.[23] 罗云,张萍,张颖,等.异基因造血干细胞移植后序贯输注供者CIK细胞治疗9例复发/难治性血液肿瘤疗效的初步探讨[J].肿瘤, 2012, 32(7):546-550.[24] Introna M, Franceschetti M, Ciocca A, et al. Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. Bone Marrow Transplant. 2006;38(9):621-627.[25] 童春容,耿彦彪,陆道培.自体细胞因子诱导的杀伤细胞治疗急性白血病的临床研究[J].北京医科大学学报,2000,32(5):473-477.[26] 陈智超,李菁媛,姚军霞,等.DC-CIK细胞治疗自体外周血造血干细胞移植后急性髓性白血病的临床研究[J].临床内科杂志,2007, 24(9):596-598. [27] 童春,郭智,楼金星,等.异基因造血干细胞移植后T淋巴细胞亚群监测的临床意义[J].中国实验血液学杂志,2016,24(1):167-172.[28] 王亮,朱康儿,张涛,等.小鼠异基因造血干细胞移植后使用G-CSF对aGVHD的影响[J].中国病理生理杂志,2015,31(12): 2188-2194.[29] 王利军,刘明娟,赵小利,等.异基因造血干细胞移植治疗45例骨髓增生异常综合征临床及预后分析[J].中国实验血液学杂志,2016, 24(2):502-509.[30] 李猛,管立勋,谷振阳,等.rhG-CSF动员对异基因造血干细胞移植供者T淋巴细胞亚群S1P5表达的影响[J].中国实验血液学杂志, 2016,24(4):1132-1136.[31] Khandelwal P, Emoto C, Fukuda T, et al. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016; 22(12):2220-2225. [32] Wang J, Luan Z, Jiang H, et al. Allogeneic Hematopoietic Stem Cell Transplantation in Thirty-Four Pediatric Cases of Mucopolysaccharidosis-A Ten-Year Report from the China Children Transplant Group. Biol Blood Marrow Transplant. 2016;22(11):2104-2108. [33] Wang L, Zhang H, Guan L, et al. Mesenchymal stem cells provide prophylaxis against acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: A meta-analysis of animal models. Oncotarget. 2016;7(38): 61764-61774.[34] Jiang X, Xu L, Zhang Y, et al. Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation. Oncoimmunology. 2016;5(5):e1139274.[35] Ye Y, Zheng W, Wang J, et al. Risk and prognostic factors of transplantation-associated thrombotic microangiopathy in allogeneic haematopoietic stem cell transplantation: a nested case control study. Hematol Oncol. 2016;5(2):78-80. [36] Gassas A, Krueger J, Schechter T, et al. Safety and Role of Gastrointestinal Endoscopy in the Management of Gastrointestinal Acute GVHD in Children After Hematopoietic Stem Cell Transplantation. J Pediatr Hematol Oncol. 2016; 38(6):453-456. |